Kevin C. Berryman
Analyst · Stifel, Nicolaus
Thank you, Hernan, and good morning and good afternoon, everyone. Turning to our quarter results, reported revenues for the fourth quarter totaled $681 million, compared with $644 million in the prior year quarter, or an increase of 6%. Our local currency sales growth increased 8%, as currency translation reduced our reported sales by 200 basis points in the quarter. On a like-for-like basis, our sales growth was 10% in the quarter. Our gross margins were 42.2% this quarter, up from 37.9% in the prior year, or an increase of 430 basis points. The improved performance was due to favorable manufacturing leverage supported by strong volume growth; ongoing cost-savings initiatives; an improved sales mix, including the benefits of exiting low-margin sales activities in Flavors; and the continued benefits of pricing, which helped to offset the continued high level of input costs. The strong sales and gross margin improvement in the quarter also resulted in higher levels of incentive compensation provisions in the quarter, resulting in research, selling and administrative expenses being higher than normal levels and certainly, well above last year, when incentive compensation provisions were abnormally low. Our sales strength and gross margin expansion, however, more than offset these increases. As a result, our adjusted operating profit increased 9% or $8 million, to $99 million in the quarter. With interest expense down slightly year-over-year and a lower effective tax rate due to a lower cost of repatriation and reductions in tax provisions, we were able to drive a 12% increase in adjusted EPS growth to $0.83, up from $0.74 in the fourth quarter of 2011. To provide additional perspective on the underlying sales growth momentum in our business, we are including a graph of our quarterly like-for-like growth by business unit and for the total consolidated company. This graph highlights the sequential improvement we have achieved in our business in each successive quarter of the year, buoyed by a strong level of new wins and an improvement in the growth of the base business. On a consolidated basis, our total company like-for-like growth showed increased momentum in every quarter, from 1% in the first quarter to 5% in the second, 7% in the third and finally, to 10% in the fourth quarter. For the full year, total company grew by 5% on a like-for-like basis. Importantly, this is the third year in a row that we have met our long-term local currency sales growth target. Looking at the business units. Flavors has shown strong and consistent growth every quarter, when eliminating the impact of exiting low-margin sales activities. On a like-for-like basis, Flavors sales growth ranged from 6% in the first quarter, to 9% in both the second and third quarters. For the full year, Flavors like-for-like growth was 8%. Turning to our Fragrance business. An improving growth trend in our business was seen in every quarter, buoyed by new business wins and an improving growth trend in the baseline business, combined with some pricing to recover raw material cost increases. This year, Fragrance declined 3% in the first quarter, was flat in the second, but then grew by 5% in the third and 13% in the fourth quarter. For the full year, Fragrance delivered 3% local currency sales growth. Importantly, when further evaluating the incremental growth momentum for Fragrance, it was largely driven by the combined results of our Fine & Beauty Care and Functional businesses or the Fragrance business excluding the Fragrance Ingredients sales. The improving trend here was also impressive, as growth trended up consistently over the course of the year from minus 1% in Q1, to 15% in Q4. As a result, for the full year, both Fine & Beauty Care and Functional, grew 7% -- by 7% in local currency sales. To illustrate our strength in the emerging markets, I would also like to highlight the trend in our shifting sales mix, from the developed markets to the emerging markets, over the past 3 years. As you can note, the percentage of sales in the emerging markets has increased from 44% in 2010, to 46% in 2011, and finally, to 47% in 2012. Importantly, during Q4 of 2012, at least 50% or more of our sales on our Compounds businesses, which are those businesses excluding our Fragrance Ingredients sales, were to the emerging markets. Specifically in Q4, the emerging markets accounted for 50% of all Flavors sales and 53% of our combined Fine & Beauty Care and Functional sales levels. At this rate, we believe we are well on track to have more than 50% of our total sales come from the emerging markets by 2015, consistent with the strategic objectives we have set for ourselves, as part of our focus to leverage our geographic reach. Turning to raw material costs. As you know, we have been closely monitoring our input costs and this is the first quarter in 8 quarters where we've actually seen them decline, albeit at a modest level, down less than 2%. While that was nice to see, as many of you already know and which has been mentioned already, we have faced significant input cost pressure over the last 2 years. In fact, over the last 2 years, we have seen our input costs rise by 14%. While both businesses faced significant cost pressure, it was more significant in Fragrances, where strong increases in naturals, petrochemicals and feedstock ingredients drove strong double-digit increases in input costs. Nevertheless, our gross margin improvement versus year ago for the quarter and full year was 430 and 210 basis points, respectively, and was driven by strong innovations, improved product mix, cost-savings initiatives and the exit of low-margin sales activity. Importantly, with the recent margin expansion, our margins have now recovered back to levels we saw in 2010, before the raw material costs began to rise. And the net benefit of pricing input costs movements in the fourth quarter, represented actually less than 1/3 of the total improvement in gross margin for this period. Simply put, advances in our gross margin for both Q4 and for the full year are fundamentally being driven by our execution against our strategy, which calls for driving innovation, optimizing our portfolio and driving efficiency in everything that we do. Looking ahead to 2013, based on our current outlook. We expect raw material costs to be relatively benign, which will result in costs that are flat to slightly increasing. From an overhead cost standpoint, adjusted research, selling and administrative costs or RSA costs, as a percentage of sales, increased 380 basis points this quarter, to 27.6%, up from 23.8% of sales in the prior year quarter. This increase reflects higher incentive compensation provisions this year, due to achieving stronger volume growth versus expectations from Q4 and its impact on our performance versus our full year targets. As a result, the fourth quarter RSA expense contains incentive compensation provisions above more normalized levels and certainly, well above last year when provisions were abnormally low. Excluding the impact of the increased incentive compensation accrual for the current year quarter, adjusted RSA as a percent of sales would have actually fallen versus a year ago. This would result in a more normal level of leverage associated with our business model, whereby our growth would result in improved absorption of our fixed cost structure. Importantly, R&D investments continue to increase in support of our strategic pillar to enhance our innovation efforts. Regarding foreign currency impacts. In the fourth quarter, foreign currency had a 200 basis-point impact on our top line, but a limited impact on our bottom line performance. Importantly, due to our cash flow hedging activities, there was limited impact on the fourth quarter year-over-year operating profit margin. In short, our exposure to euro volatility in 2012 was significantly reduced, as a result of our hedging efforts. Looking ahead to 2013. We are now nearly 80% hedged against the euro levels that approximate $1.29, effectively a rate that is consistent with the average exchange rate level for the full year 2012. For 2012, cash flows from operations were $333 million or 11.8% of sales, compared with $189 million or 6.8% of sales for 2011. Of note, the cash flow in 2012 includes $105 million payment related to the Spanish tax settlement announced in Q3 of 2012. Cash flow from operations in 2011 includes a $40 million payment for a patent litigation settlement. If we exclude these aggregate payments from both years, our operating cash flow would have nearly doubled from $222.5 million to $438.5 million, a clear indication of the strength of our operating model. Our strong operating cash flow provides us with the ability to continue to make targeted investments in the growth of our business, targeting those projects with the greatest return, while also returning cash to our shareholders. This year, we made capital investments totaling $126 million or nearly 5% of our sales, including new facilities in Singapore and China. We expect to have a similar level of spending, as a percent of sales, in 2013. In 2012, we also increased our quarterly dividend by $0.03, or nearly 10% to $0.34. And in the fourth quarter, we paid out our dividend that is usually and typically paid in January, in December. We also announced a $250 million stock repurchase program, which will enable the company to purchase nearly 5% of its outstanding shares, based on the market price of our shares on December 31, 2012. Finally, it is important to note that the cash flow conversion rate, measured as the conversion of net income into operating cash flow, and adjusting for the payments related to the patent settlement in 2011 and tax settlement in 2012, increased in 2012 1.3x [ph] from 0.7x in 2011. On this basis, looking at a 2-year average, our operating cash flow to net income conversion rate is at a healthy 1.0x. In summary, 2012 was an exciting year for IFF. We delivered broad-based top line performance, led by growth in the emerging markets. We were able to achieve local currency sales growth in line with our long-term targets for the third year in a row, due to the stability of our business, in which diversification of categories, products and customers supported our performance. Our ability to anticipate consumer preferences with innovative products, such as those using our sweetness and sodium modulation tools in Flavors, or those using our encapsulation technology in Fragrances, were critical drivers to our new win successes. Our gross margin expansion was due to many different factors, including our operating leverage, continued cost discipline and cost-reduction efforts, strong innovation, improved product mix, including the exit of low-margin sales activities, and continued pricing actions to help offset the high level of input costs. Importantly, the operating results we achieved this year enabled us to invest in our business growth and to make changes in our capital structure. We have invested, and continue to invest, in additional capacity and creative centers in the emerging markets of Asia. We are building a facility in Turkey, and we'll look for other opportunities to add capacity in those markets, where changing demographics result in increased demand for customer products. We continue to invest more than 8% of sales annually on R&D programs, and as a result, we have a very strong pipeline of products based on our key R&D platforms. The business generates strong cash flow, and our quarterly dividend and authorization of a $250 million stock buyback program are indications of our confidence in the future. With that, I'd like to turn the call over to Doug for his outlook on 2013.